Inhibition of STAT5 in conjunction with standard TKI therapy  - CML

ARTICLES

New discovery could soon make leukemia history
June 11, 2014, Business Standard

Breakthrough in cancer research as treatment is developed that gets cancer cells to kill themselves: 'Paradigm-shifting' discovery will DRAMATICALLY reduce side effects and need for ongoing therapy
June 10, 2014,  Mail Online

Game Changer for Leukemia Therapy
June 10, 2014, Newswise

BCR-ABL Affects STAT5A and STAT5B Differentially
May 16, 2014, ResearchGate

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia
May 12, 2014,  Journal Leukemia

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
March 1, 2014, Haematologica

STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner
2013, Journal Blood

STAT5 as a CML target: STATinib therapies?
March 24, 2011, Journal Blood

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
December 27, 2010, Journal Blood

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
April 6, 2007, Molecular Cancer Therapeutics

STAT5 signaling is required for the efficient induction and maintenance of CML in mice
June 15, 2006, Journal Blood

Effect of curcumin on STAT5 signaling pathway in primary CML cells
October 12, 2004, PublMed

                   See also Combination of pioglitazone with tyrosine kinase inhibitor      
                
                                     Return to Cure possible for CML?